Neuropsychiatric systemic lupus erythematosus (1st part). Cases definitions and diagnosis and treatment of central nervous system and psychiatric manifestations of systemic lupus erythematosus;Neurolupus (1 re partie). Description et démarche diagnostique et thérapeutique dans les manifestations neurologiques centrales et psychiatriques au cours du lupus érythémateux systémique

Revue de Medecine Interne

Volumn 33, Issue 9, 2012, Pages 491-502

  Lefevre G ^a   Zephir H ^a   Warembourg, F ^a   Michelin, E ^a   Pruvo, J P ^a   Hachulla, E ^a   Semah, F ^a   Dubucquoi, S ^a   Lenfant, P ^a   Vermersch, P ^a   Hatron, P Y ^a   Prin, L ^a   Launay, D ^a  

^a UNIV LILLE   (France)

Author keywords

Antiphospholipids; Neuropsychiatric systemic lupus erythematosus; Systemic lupus erythematosus

Indexed keywords

CLINICAL FEATURE; HUMAN; NEUROPSYCHIATRY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; ANXIETY DISORDER; BRAIN VASCULITIS; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; EPILEPSY; NEUROPSYCHOLOGICAL TEST; REVIEW;

ANXIETY DISORDERS; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; EPILEPSY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; NEUROPSYCHOLOGICAL TESTS; PREVALENCE;

EID: 84868301221     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.03.356     Document Type: Short Survey

References (135)

1. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
2. Ainiala H., Hietaharju A., Loukkola J., Peltola J., Korpela M., Metsanoja R., et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001, 45:419-423.
3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
4. Bertsias G.K., Ioannidis J.P., Aringer M., Bollen E., Bombardieri S., Bruce I.N., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
5. e partie): description des outils diagnostiques et thérapeutiques devant une manifestation psychiatrique ou neurologique centrale au cours du lupus érythémateux systémique. Rev Med Interne 2012, in press. 10.1016/j.revmed.2012.03.354.
6. Afeltra A., Garzia P., Mitterhofer A.P., Vadacca M., Galluzzo S., Del Porto F., et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003, 61:108-110.
7. Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D., Stallworth C.L., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214-1220.
8. Harboe E., Tjensvoll A.B., Maroni S., Goransson L.G., Greve O.J., Beyer M.K., et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann Rheum Dis 2009, 68:1541-1546.
9. Sanna G., Bertolaccini M.L., Cuadrado M.J., Laing H., Khamashta M.A., Mathieu A., et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003, 30:985-992.
10. Tam L.S., Wong A., Mok V.C., Zhu Y.E., Kwok L.W., Li T.K., et al. The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J Rheumatol 2008, 35:1038-1045.
11. Abdel-Nasser A.M., Ghaleb R.M., Mahmoud J.A., Khairy W., Mahmoud R.M. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 2008, 27:1377-1385.
12. Mok C.C., Lau C.S., Wong R.W. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001, 28:766-771.
13. Appenzeller S., Cendes F., Costallat L.T. Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum 2009, 61:680-687.
14. Avcin T., Benseler S.M., Tyrrell P.N., Cucnik S., Silverman E.D. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008, 59:206-213.
15. Olfat M.O., Al-Mayouf S.M., Muzaffer M.A. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004, 23:395-399.
16. Sibbitt W.L., Brandt J.R., Johnson C.R., Maldonado M.E., Patel S.R., Ford C.C., et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002, 29:1536-1542.
17. Spinosa M.J., Bandeira M., Liberalesso P.B., Vieira S.C., Janz L.L., Sa E.G., et al. Clinical, laboratory and neuroimage findings in juvenile systemic lupus erythematosus presenting involvement of the nervous system. Arq Neuropsiquiatr 2007, 65:433-439.
18. Yu H.H., Lee J.H., Wang L.C., Yang Y.H., Chiang B.L. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 2006, 15:651-657.
19. Harel L., Sandborg C., Lee T., von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006, 33:1873-1877.
20. Unterman A., Nolte J.E., Boaz M., Abady M., Shoenfeld Y., Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2010.
21. Mok C.C., To C.H., Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006, 85:221-228.
22. Hanly J.G., Urowitz M.B., Su L., Bae S.C., Gordon C., Wallace D.J., et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010, 69:529-535.
23. Zhou H.Q., Zhang F.C., Tian X.P., Leng X.M., Lu J.J., Zhao Y., et al. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus 2008, 17:93-99.
24. Davey R., Bamford J., Emery P. The ACR classification criteria for headache disorders in SLE fail to classify certain prevalent headache types. Cephalalgia 2008, 28:296-299.
25. Sfikakis P.P., Mitsikostas D.D., Manoussakis M.N., Foukaneli D., Moutsopoulos H.M. Headache in systemic lupus erythematosus: a controlled study. Br J Rheumatol 1998, 37:300-303.
26. Mitsikostas D.D., Sfikakis P.P., Goadsby P.J. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004, 127:1200-1209.
27. Lessa B., Santana A., Lima I., Almeida J.M., Santiago M. Prevalence and classification of headache in patients with systemic lupus erythematosus. Clin Rheumatol 2006, 25:850-853.
28. Weder-Cisneros N.D., Tellez-Zenteno J.F., Cardiel M.H., Guibert-Toledano M., Cabiedes J., Velasquez-Paz A.L., et al. Prevalence and factors associated with headache in patients with systemic lupus erythematosus. Cephalalgia 2004, 24:1031-1044.
29. Fujieda Y., Kataoka H., Odani T., Otomo K., Kato M., Fukaya S., et al. Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. Mod Rheumatol 2011.
30. Baizabal-Carvallo J.F., Barragan-Campos H.M., Padilla-Aranda H.J., Alonso-Juarez M., Estanol B., Cantu-Brito C., et al. Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 2009, 111:359-363.
31. Zhang Y.X., Liu J.R., Ding M.P., Huang J., Zhang M., Jansen O., et al. Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis. Intern Med 2008, 47:867-875.
32. Omdal R., Husby G., Mellgren S.I. Mental health status in systemic lupus erythematosus. Scand J Rheumatol 1995, 24:142-145.
33. Sundquist K., Li X., Hemminki K., Sundquist J. Subsequent risk of hospitalization for neuropsychiatric disorders in patients with rheumatic diseases: a nationwide study from Sweden. Arch Gen Psychiatry 2008, 65:501-507.
34. Lindal E., Thorlacius S., Steinsson K., Stefansson J.G. Psychiatric disorders among subjects with systemic lupus erythematosus in an unselected population. Scand J Rheumatol 1995, 24:346-351.
35. Nery F.G., Borba E.F., Hatch J.P., Soares J.C., Bonfa E., Neto F.L. Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry 2007, 48:14-19.
36. Segui J., Ramos-Casals M., Garcia-Carrasco M., de Flores T., Cervera R., Valdes M., et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus 2000, 9:584-588.
37. Iaboni A., Ibanez D., Gladman D.D., Urowitz M.B., Moldofsky H. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. J Rheumatol 2006, 33:2453-2457.
38. Bachen E.A., Chesney M.A., Criswell L.A. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009, 61:822-829.
39. Jump R.L., Robinson M.E., Armstrong A.E., Barnes E.V., Kilbourn K.M., Richards H.B. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005, 32:1699-1705.
40. Kozora E., Arciniegas D.B., Zhang L., West S. Neuropsychological patterns in systemic lupus erythematosus patients with depression. Arthritis Res Ther 2007, 9:R48.
41. Kozora E., Ellison M.C., West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006, 55:628-635.
42. Petri M., Naqibuddin M., Carson K.A., Wallace D.J., Weisman M.H., Holliday S.L., et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 2010, 37:2032-2038.
43. Brelinski L., Cottencin O., Guardia D., Anguill J.D., Queyrel V., Hatron P.Y., et al. Catatonia and systemic lupus erythematosus: a clinical study of three cases. Gen Hosp Psychiatry 2009, 31:90-92.
44. Fricchione G.L., Kaufman L.D., Gruber B.L., Fink M. Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia. Am J Med 1990, 88:442-443.
45. Malur C., Pasol E., Francis A. ECT for prolonged catatonia. J Ect 2001, 17:55-59.
46. Marra D., Amoura Z., Soussan N., Haroche J., Consoli A., Ghillami-Dalbin P., et al. Plasma exchange in patients with stuporous catatonia and systemic lupus erythematosus. Psychother Psychosom 2008, 77:195-196.
47. Wang H.Y., Huang T.L. Benzodiazepines in catatonia associated with systemic lupus erythematosus. Psychiatry Clin Neurosci 2006, 60:768-770.
48. Julian L.J., Yelin E., Yazdany J., Panopalis P., Trupin L., Criswell L.A., et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009, 61:240-246.
49. Karassa F.B., Magliano M., Isenberg D.A. Suicide attempts in patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:58-60.
50. Matsukawa Y., Sawada S., Hayama T., Usui H., Horie T. Suicide in patients with systemic lupus erythematosus: a clinical analysis of seven suicidal patients. Lupus 1994, 3:31-35.
51. Kozora E., Arciniegas D.B., Filley C.M., West S.G., Brown M., Miller D., et al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 2008, 59:1639-1646.
52. Mikdashi J.A., Esdaile J.M., Alarcon G.S., Crofford L., Fessler B.J., Shanberg L., et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007, 16:418-425.
53. Tomietto P., Annese V., D'Agostini S., Venturini P., La Torre G., De Vita S., et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 2007, 57:1461-1472.
54. McLaurin E.Y., Holliday S.L., Williams P., Brey R.L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005, 64:297-303.
55. Monastero R., Bettini P., Del Zotto E., Cottini E., Tincani A., Balestrieri G., et al. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci 2001, 184:33-39.
56. Appenzeller S., Rondina J.M., Li L.M., Costallat L.T., Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005, 52:2783-2789.
57. Ainiala H., Dastidar P., Loukkola J., Lehtimaki T., Korpela M., Peltola J., et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol 2005, 34:376-382.
58. Harrison M.J., Morris K.A., Horton R., Toglia J., Barsky J., Chait S., et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 2005, 65:1325-1327.
59. Panopalis P., Julian L., Yazdany J., Gillis J.Z., Trupin L., Hersh A., et al. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum 2007, 57:1453-1460.
60. Mikdashi J., Krumholz A., Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005, 64:2102-2107.
61. Appenzeller S., Cendes F., Costallat L.T. Epileptic seizures in systemic lupus erythematosus. Neurology 2004, 63:1808-1812.
62. Gonzalez-Duarte A., Cantu-Brito C.G., Ruano-Calderon L., Garcia-Ramos G. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008, 59:320-323.
63. Lampropoulos C.E., Koutroumanidis M., Reynolds P.P., Manidakis I., Hughes G.R., D'Cruz D.P. Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum 2005, 52:841-846.
64. Hak A.E., Karlson E.W., Feskanich D., Stampfer M.J., Costenbader K.H. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 2009, 61:1396-1402.
65. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
66. Bruce I.N. 'Not only but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:1492-1502.
67. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
68. Roldan C.A., Gelgand E.A., Qualls C.R., Sibbitt W.L. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005, 95:1441-1447.
69. Roldan C.A., Qualls C.R., Sopko K.S., Sibbitt W.L. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol 2008, 35:224-229.
70. Wahl D.G., Bounameaux H., de Moerloose P., Sarasin F.P. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000, 160:2042-2048.
71. Wajed J., Ahmad Y., Durrington P.N., Bruce I.N. Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) 2004, 43:7-12.
72. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I., Brey R., Crowther M., Derksen R., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011, 20:206-218.
73. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007, 57:1487-1495.
74. Nery F.G., Borba E.F., Viana V.S., Hatch J.P., Soares J.C., Bonfa E., et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:695-700.
75. Kozora E., Ellison M.C., Waxmonsky J.A., Wamboldt F.S., Patterson T.L. Major life stress, coping styles, and social support in relation to psychological distress in patients with systemic lupus erythematosus. Lupus 2005, 14:363-372.
76. Edworthy S.M., Dobkin P.L., Clarke A.E., Da Costa D., Dritsa M., Fortin P.R., et al. Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. J Rheumatol 2003, 30:1011-1016.
77. Navarrete-Navarrete N., Peralta-Ramirez M.I., Sabio-Sanchez J.M., Coin M.A., Robles-Ortega H., Hidalgo-Tenorio C., et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom 2010, 79:107-115.
78. Pego-Reigosa J.M., Isenberg D.A. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008, 47:1498-1502.
79. Appenzeller S., Cendes F., Costallat L.T. Acute psychosis in systemic lupus erythematosus. Rheumatol Int 2008, 28:237-243.
80. Kodama K., Okada S., Hino T., Takabayashi K., Nawata Y., Uchida Y., et al. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995, 58:307-311.
81. Pace A.V., Erb N., Kitas G.D. Sunlight-induced recurrent acute confusion as the initial presentation of systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40:108-109.
82. Dennis M.S., Byrne E.J., Hopkinson N., Bendall P. Neuropsychiatric systemic lupus erythematosus in elderly people: a case series. J Neurol Neurosurg Psychiatry 1992, 55:1157-1161.
83. Heckman G.A., Papaioannou A., Adachi J.D., Denburg J.A. Systemic lupus erythematosus presenting as subacute delirium in an 82-year-old woman. J Am Geriatr Soc 2001, 49:458-461.
84. Calabrese L.H., Molloy E.S., Huang D., Ransohoff R.M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007, 56:2116-2128.
85. Lefevre G., Queyrel V., Maurage C.A., Laurent C., Launay D., Lacour A., et al. Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. J Neurol Sci 2009, 287:246-249.
86. Birnbaum J., Petri M., Thompson R., Izbudak I., Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009, 60:3378-3387.
87. Espinosa G., Mendizabal A., Minguez S., Ramo-Tello C., Capellades J., Olive A., et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2010, 39:246-256.
88. Kovacs B., Lafferty T.L., Brent L.H., DeHoratius R.J. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000, 59:120-124.
89. Lu X., Gu Y., Wang Y., Chen S., Ye S. Prognostic factors of lupus myelopathy. Lupus 2008, 17:323-328.
90. Tellez-Zenteno J.F., Remes-Troche J.M., Negrete-Pulido R.O., Davila-Maldonado L. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 2001, 10:851-856.
91. Theodoridou A., Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006, 77:290-295.
92. D'Cruz D.P., Mellor-Pita S., Joven B., Sanna G., Allanson J., Taylor J., et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004, 31:280-285.
93. Marignier R., Giraudon P., Vukusic S., Confavreux C., Honnorat J. Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord 2010, 3:311-321.
94. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
95. Delalande S., De Seze J., Ferriby D., Vermersch P. Neurological manifestations in Sjogren syndrome. Rev Med Interne 2010, 31(Suppl. 1):S8-S15.
96. Jacob A., Weinshenker B.G. An approach to the diagnosis of acute transverse myelitis. Semin Neurol 2008, 28:105-120.
97. Harisdangkul V., Doorenbos D., Subramony S.H. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol 1995, 242:326-331.
98. Ferreira S., D'Cruz D.P., Hughes G.R. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. Rheumatology (Oxford) 2005, 44:434-442.
99. Rovaris M., Viti B., Ciboddo G., Capra R., Filippi M. Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. J Neurol Sci 2000, 176:128-130.
100. Mok M.Y., Chan E.Y., Wong W.S., Lau C.S. Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations. Ann Rheum Dis 2007, 66:846-847.
101. West S.G., Emlen W., Wener M.H., Kotzin B.L. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995, 99:153-163.
102. Garg N., Zivadinov R., Ramanathan M., Vasiliu I., Locke J., Watts K., et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 2007, 187:159-165.
103. Cervera R., Asherson R.A., Font J., Tikly M., Pallares L., Chamorro A., et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997, 76:203-212.
104. Orzechowski N.M., Wolanskyj A.P., Ahlskog J.E., Kumar N., Moder K.G. Antiphospholipid antibody-associated chorea. J Rheumatol 2008, 35:2165-2170.
105. Dale R.C., Singh H., Troedson C., Pillai S., Gaikiwari S., Kozlowska K. A prospective study of acute movement disorders in children. Dev Med Child Neurol 2010, 52:739-748.
106. Hatron P.Y., Bouchez B., Wattel A., Arnott G., Devulder B. Chorea, systemic lupus erythematosus, circulating lupus anticoagulant. J Rheumatol 1986, 13:991-993.
107. Galanaud D., Dormont D., Marsault C., Wechsler B., Piette J.C. Brain MRI in patients with past lupus-associated chorea. Stroke 2000, 31:3079-3083.
108. Sunden-Cullberg J., Tedroff J., Aquilonius S.M. Reversible chorea in primary antiphospholipid syndrome. Mov Disord 1998, 13:147-149.
109. Wu S.W., Graham B., Gelfand M.J., Gruppo R.E., Dinopolous A., Gilbert D.L. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord 2007, 22:1813-1815.
110. Guttman M., Lang A.E., Garnett E.S., Nahmias C., Firnau G., Tyndel F.J., et al. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. Mov Disord 1987, 2:201-210.
111. Krakauer M., Law I. FDG PET brain imaging in neuropsychiatric systemic lupus erythematosis with choreic symptoms. Clin Nucl Med 2009, 34:122-123.
112. Dale R.C., Yin K., Ding A., Merheb V., Varadkhar S., McKay D., et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol 2011, 53:522-528.
113. Jennekens F.G., Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002, 41:605-618.
114. Orta Daniel S.J., Ulises R.O. Stroke of the substance nigra and parkinsonism as first manifestation of systemic lupus erythematosus. Parkinsonism Relat Disord 2008, 14:367-369.
115. Kunas R.C., McRae A., Kesselring J., Villiger P.M. Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. J Allergy Clin Immunol 1995, 96:688-690.
116. Kwong K.L., Chu R., Wong S.N. Parkinsonism as unusual neurological complication in childhood systemic lupus erythematosus. Lupus 2000, 9:474-477.
117. Garcia-Moreno J.M., Chacon J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord 2002, 17:1329-1335.
118. Miyoshi Y., Atsumi T., Kitagawa H., Ogura N., Amasaki Y., Tsutsumi A., et al. Parkinson-like symptoms as a manifestation of systemic lupus erythematosus. Lupus 1993, 2:199-201.
119. Lee P.H., Joo U.S., Bang O.Y., Seo C.H. Basal ganglia hyperperfusion in a patient with systemic lupus erythematosus-related parkinsonism. Neurology 2004, 63:395-396.
120. Osawa H., Yamabe H., Kaizuka M., Tamura N., Tsunoda S., Shirato K.I., et al. Systemic lupus erythematosus associated with transverse myelitis and parkinsonian symptoms. Lupus 1997, 6:613-615.
121. Hung J.J., Ou L.S., Lee W.I., Huang J.L. Central nervous system infections in patients with systemic lupus erythematosus. J Rheumatol 2005, 32:40-43.
122. Moris G., Garcia-Monco J.C. The challenge of drug-induced aseptic meningitis. Arch Intern Med 1999, 159:1185-1194.
123. Baizabal-Carvallo J.F., Delgadillo-Marquez G., Estanol B., Garcia-Ramos G. Clinical characteristics and outcomes of the meningitides in systemic lupus erythematosus. Eur Neurol 2009, 61:143-148.
124. Gerona J.G., Navarra S.V. Salmonella infections in patients with systemic lupus erythematosus: a case series. Int J Rheum Dis 2009, 12:319-323.
125. Gonzalez LA, Vasquez G, Restrepo JP, Velasquez M, Ramirez LA. Cryptococcosis in systemic lupus erythematosus: a series of six cases. Lupus;19:639-45.
126. Tobon G.J., Serna M.J., Canas C.A. Listeria monocytogenes infection in patients with systemic lupus erythematosus. Clin Rheumatol 2010, 7. 10.1007/s10067-010-1416-4.
127. Sanna G., Bertolaccini M.L., Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003, 12:935-942.
128. Chau S.Y., Mok C.C. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003, 61:104-107.
129. Lopez-Medrano F., Cervera R., Trejo O., Font J., Ingelmo M. Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin level. Ann Rheum Dis 2002, 61:562-563.
130. Nishimura K., Harigai M., Omori M., Sato E., Hara M. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology 2008, 33:395-403.
131. Ayadi N., Cheikhrouhou M.R., Kechaou M., Bahloul Z., Jawa A. Hypomania under corticotherapy. About 50 cases. Therapie 2007, 62:443-447.
132. Rosebush P.I., Hildebrand A.M., Furlong B.G., Mazurek M.F. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990, 51:357-362.
133. Association A.P. Diagnostic and statistical manual of mental disorders, DSM-IV 1994, American Psychiatric Association, Washington, DC. 4th ed.
134. Cottencin O., Warembourg F., de Chouly de Lenclave M.B., Lucas B., Vaiva G., Goudemand M., et al. Catatonia and consultation-liaison psychiatry study of 12 cases. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1170-1176.
135. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007, 64:1123-1231.